Cellectis, VitamFero in pact to develop vaccines for parasitic infection
As per the agreement, Cellectis is responsible for supplying preselected meganucleases to VitamFero to utilize in the development of vaccines against parasites responsible for toxoplasmosis, neosporosis, and others.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.